MXPA05006271A - Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico. - Google Patents

Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.

Info

Publication number
MXPA05006271A
MXPA05006271A MXPA05006271A MXPA05006271A MXPA05006271A MX PA05006271 A MXPA05006271 A MX PA05006271A MX PA05006271 A MXPA05006271 A MX PA05006271A MX PA05006271 A MXPA05006271 A MX PA05006271A MX PA05006271 A MXPA05006271 A MX PA05006271A
Authority
MX
Mexico
Prior art keywords
lower alkyl
movement disorders
acid derivatives
treating movement
barbituric acid
Prior art date
Application number
MXPA05006271A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Aaron Moros
Original Assignee
Taro Pharmaceuticals Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceuticals Ind Ltd filed Critical Taro Pharmaceuticals Ind Ltd
Publication of MXPA05006271A publication Critical patent/MXPA05006271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA05006271A 2002-12-11 2003-12-11 Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico. MXPA05006271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43247002P 2002-12-11 2002-12-11
PCT/US2003/039530 WO2004052350A2 (en) 2002-12-11 2003-12-11 Method of treating movement disorders using barbituric acid derivatives

Publications (1)

Publication Number Publication Date
MXPA05006271A true MXPA05006271A (es) 2006-01-30

Family

ID=32507936

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006271A MXPA05006271A (es) 2002-12-11 2003-12-11 Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.

Country Status (17)

Country Link
US (3) US7166610B2 (enExample)
EP (2) EP2156839A1 (enExample)
JP (1) JP4739760B2 (enExample)
CN (2) CN100502871C (enExample)
AR (1) AR042444A1 (enExample)
AT (1) ATE413867T1 (enExample)
AU (2) AU2003302897C1 (enExample)
BR (1) BR0317289A (enExample)
CA (1) CA2505335C (enExample)
CL (1) CL2003002588A1 (enExample)
DE (1) DE60324703D1 (enExample)
ES (1) ES2315569T3 (enExample)
IL (1) IL168853A (enExample)
MX (1) MXPA05006271A (enExample)
PT (1) PT1569627E (enExample)
TW (2) TW200822927A (enExample)
WO (1) WO2004052350A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
JP4739760B2 (ja) 2002-12-11 2011-08-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド バルビツール酸誘導体を使用する運動障害の治療方法
WO2006003651A2 (en) * 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
EP2755945A1 (en) * 2011-09-12 2014-07-23 Council of Scientific & Industrial Research ARYLATED beta-DICARBONYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
IT201700059814A1 (it) * 2017-05-31 2018-12-01 Antonio Costantini Vitamina b1 in alte dosi per uso nel trattamento medico di alcune malattie neurodegenerative sporadiche , di origine genetica e delle cefalee primarie
JP7357432B2 (ja) 2017-10-10 2023-10-06 信越化学工業株式会社 Ｅｕｖ用ペリクルフレーム、ペリクル、ペリクル付露光原版、露光方法、及び半導体の製造方法
PE20241186A1 (es) * 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1960170A (en) * 1934-05-22 Cc - phenylethyl - n -
US2119701A (en) 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
US2673205A (en) * 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
DE946804C (de) 1952-02-28 1956-08-09 Emanuel Merck Ohg Verfahren zur Herstellung von schwefelhaltigen Abkoemmlingen der Barbitursaeure
DE1103339B (de) 1959-02-04 1961-03-30 Chemische Werke Radebeul Veb Verfahren zur Herstellung von in 5-Stellung crotylierten, basisch substituierten Barbitursaeure-derivaten
DE1100639B (de) 1959-03-24 1961-03-02 Chemische Werke Radebeul Veb Verfahren zur Herstellung von basisch substituierten Barbitursaeure-derivaten
GB966098A (en) 1959-11-23 1964-08-06 Sapos Sa Barbiturate derivatives
US3930006A (en) 1963-04-30 1975-12-30 Aspro Nicholas Ltd Antiparkinsonism compositions and method
US4046894A (en) * 1968-08-05 1977-09-06 Bristol-Myers Company Certain barbituric acid derivatives used as anticonvulsant agents
US3679683A (en) 1970-05-11 1972-07-25 Exxon Research Engineering Co Barbiturate 3-n-methylene phosphates
US3711607A (en) * 1971-03-17 1973-01-16 Kendall & Co N,n -dihalomethyl phenobarbital for the treatment of convulsions
US3919427A (en) * 1972-06-02 1975-11-11 Kendall & Co Therapeutic compositions containing 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3904627A (en) * 1972-06-02 1975-09-09 Kendall & Co 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3900475A (en) * 1972-06-26 1975-08-19 Kendall & Co Certain phenobarbital salts
US3948896A (en) * 1973-02-28 1976-04-06 The Kendall Company N-mono(alkoxymethyl) phenobarbitals, process therefor and therapeutic composition and method containing same
US4060528A (en) * 1975-10-08 1977-11-29 Janssen Pharmaceutica N.V. Aroyl-substituted phenylmalonic acid derivatives
US4029662A (en) * 1976-04-30 1977-06-14 Bristol-Myers Company Method of making barbituric acid derivatives
DE2622981A1 (de) 1976-05-21 1977-12-08 Unisearch Ltd Verfahren zur herstellung von halogenalkylierten verbindungen
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
DE3374684D1 (en) * 1982-08-31 1988-01-07 Daikin Ind Ltd A method to trap the enolate ion of the malonic acid or its derivatives
IL69722A (en) 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4631294A (en) * 1985-07-05 1986-12-23 University E.M., Inc. Treatment of cerebral ischemia with dichloroacetate
IT1196500B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Derivati dell'acido malonico e metodi per la loro sintesi
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
DE4028040A1 (de) 1990-09-05 1992-03-12 Chemie Linz Deutschland Verfahren zur n-alkylierung von harnstoffen
US5456851A (en) 1994-04-07 1995-10-10 Johnson & Johnson Consumer Products, Inc. Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE19504623A1 (de) 1995-02-13 1996-08-14 Bayer Ag Verfahren zur Herstellung von N-substituierten cyclischen Imiden
RU2147584C1 (ru) * 1995-10-27 2000-04-20 Американ Цианамид Компани Способ получения дигалоидазолопиримидинов и способ получения дигидроксиазолопиримидинов
KR100194535B1 (ko) * 1995-12-27 1999-06-15 우종일 아릴 벤조일 우레아 유도체 및 이를 함유하는 농약조성물
US6184238B1 (en) * 1996-12-26 2001-02-06 Nikken Chemicals Co., Ltd. N-hydroxyurea derivative and pharmaceutical composition containing the same
US5756815A (en) * 1997-03-18 1998-05-26 American Cyanamid Company Process for the preparation arylamalonates
US5750766A (en) * 1997-03-18 1998-05-12 American Cyanamid Company Process for the preparation of arylmalonates
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
CA2331735A1 (en) * 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
JP2002516315A (ja) 1998-05-26 2002-06-04 ナチュラル ドラッグ サイエンシズ，リミティド ライアビリティ カンパニー ５−オキシミノバルビツール酸のｎ−置換誘導体
US6156925A (en) * 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
CA2392879C (en) 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
CA2306170A1 (en) 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
WO2002007729A1 (en) 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1485101A4 (en) 2002-01-30 2006-04-12 Taro Pharma Ind NON-SURFACTANT BARBITIC ACID DERIVATIVES
JP4739760B2 (ja) * 2002-12-11 2011-08-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド バルビツール酸誘導体を使用する運動障害の治療方法
WO2006003651A2 (en) 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES

Also Published As

Publication number Publication date
TWI334780B (en) 2010-12-21
PT1569627E (pt) 2009-01-20
ES2315569T3 (es) 2009-04-01
EP1569627A2 (en) 2005-09-07
US7166610B2 (en) 2007-01-23
US8314115B2 (en) 2012-11-20
AU2003302897A1 (en) 2004-06-30
US7776871B2 (en) 2010-08-17
JP4739760B2 (ja) 2011-08-03
CA2505335A1 (en) 2004-06-24
CL2003002588A1 (es) 2005-01-07
CA2505335C (en) 2013-09-10
CN101569626B (zh) 2012-02-08
JP2006510659A (ja) 2006-03-30
AU2003302897B2 (en) 2009-12-03
IL168853A (en) 2011-07-31
CN100502871C (zh) 2009-06-24
US20040186120A1 (en) 2004-09-23
AU2010200787A1 (en) 2010-03-25
WO2004052350A3 (en) 2004-09-23
TW200822927A (en) 2008-06-01
AU2003302897C1 (en) 2010-07-08
CN1717235A (zh) 2006-01-04
TW200418481A (en) 2004-10-01
US20100311771A1 (en) 2010-12-09
BR0317289A (pt) 2005-11-08
DE60324703D1 (de) 2008-12-24
AR042444A1 (es) 2005-06-22
US20070072886A1 (en) 2007-03-29
CN101569626A (zh) 2009-11-04
WO2004052350A2 (en) 2004-06-24
EP2156839A1 (en) 2010-02-24
EP1569627B1 (en) 2008-11-12
ATE413867T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
SE0104334D0 (sv) Therapeutic agents
MY135841A (en) Novel benzodioxoles
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
AP1895A (en) Novel benzoimidazole derivatives useful as antiproliferative agents.
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
TW200517109A (en) Substituted pyridinones
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
EG25822A (en) Quinolinyl-pyrrolopyrazoles
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
CY1107411T1 (el) Θεραπευτικα παραγωγα πιπεραζινης χρησιμα για την αγωγη του πονου
WO2004029031A3 (en) Therapeutic piperazine compounds
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
WO2004052350A3 (en) Method of treating movement disorders using barbituric acid derivatives
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
NO20013409L (no) Anvendelse av pyrimidin-derivater for forhindring og behandling av cerebral ischemi
TW200503732A (en) Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives and methods of use thereof
NZ332687A (en) use of 1-methyl-carbapenem derivatives as anti-helicobacter pylori agents
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis

Legal Events

Date Code Title Description
FG Grant or registration